Olympics anti-doping team to pursue biomarkers after the games

The U.K. pieced together an ambitious collaboration of researchers and industry leaders to create an anti-doping facility for the Olympics. And after the athletes are done competing, the research team intends to go on in its own pursuit for the gold. Only they'll be competing in the personalized medicine field, looking for new biomarkers. GlaxoSmithKline ($GSK) is providing the facilities for the Olympics. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.